http://www.arrowres.com/ Arrowhead Research Corp.: Nanotech with a point en-us Copyright 2011, Arrowhead Research Corporation Thu, 02 Feb 2012 07:05:10 -0500 Thu, 02 Feb 2012 07:05:10 -0500 60 http://www.arrowres.com/images/links/logo_about1.gif http://www.arrowres.com/ 100 88 Arrowhead Research Corp.: Nanotech with a point http://www.arrowres.com/publications/2012/february02_2012.html PASADENA, Calif., February 2, 2012 - Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2012 first quarter ended December 31, 2011, on Thursday, February 9, 2012 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). Thu, 02 Feb 2012 07:05:10 -0500 http://www.arrowres.com/publications/2012/january05_2012.html Cambridge, Mass. and Pasadena, Calif., January 5, 2012 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Arrowhead Research Corporation, (Nasdaq: ARWR) a nanomedicine company with development programs in RNAi and obesity, announced today that they have entered into a collaboration and joint licensing agreement. Thu, 05 Jan 2012 15:05:10 -0500 http://www.arrowres.com/publications/2012/january04_2012.html PASADENA, Calif. - January 4, 2012 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced that the Investigational New Drug Application (IND) for its first obesity drug candidate, AdipotideTM, was accepted by the U.S. Food and Drug Administration allowing the initiation of a clinical trial to test the safety of the compound. Wed, 04 Jan 2012 14:35:10 -0500 http://www.arrowres.com/publications/2011/december20_2011.html PASADENA, Calif. - December 20, 2011 - Arrowhead Research Corporation (NASDAQ: ARWRD), a nanomedicine company with development programs in oncology and obesity, today announced financial results for its fiscal 2011 fourth quarter and year ended September 30, 2011. Tue, 20 Dec 2011 16:01:10 -0500 http://www.arrowres.com/publications/2011/december19_2011.html PASADENA, Calif. - December 19, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, announced today that it has appointed Michael S. Perry, Hon BSc, DVM, Ph.D., to its board of directors. Mon, 19 Dec 2011 14:00:10 -0500 http://www.arrowres.com/publications/2011/december15_2011.html PASADENA, Calif., - December 15, 2011 - Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2011 fourth quarter and year ended September 30, 2011, on Tuesday, December 20, 2011 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). Thu, 15 Dec 2011 14:10:29 -0500 http://www.arrowres.com/publications/2011/november23_2011.html PASADENA, Calif. - November 23, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that it has appointed David Lewis, Ph.D., as Vice President, Biology, and David Rozema, Ph.D., as Vice President, Chemistry, effective immediately. Wed, 23 Nov 2011 14:10:29 -0500 http://www.arrowres.com/publications/2011/november16_2011.html PASADENA, Calif. - November 16, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the implementation of a 1-for-10 reverse stock split of its common stock. Trading on a post-split basis will begin November 17, 2011 at market open. The reverse stock split was proposed by the Company's Board of Directors and approved by Arrowhead stockholders at the 2011 Annual Meeting of Shareholders held on August 8, 2011. Wed, 16 Nov 2011 16:12:29 -0500 http://www.arrowres.com/publications/2011/november14_2011.html HOUSTON, TX - November 14, 2011 - Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). Mon, 14 Nov 2011 08:10:30 -0500 http://yourlife.usatoday.com/health/healthcare/studies/story/2011-11-10/Experimental-drug-slims-obese-monkeys/51150604/1 An experimental drug that targets and kills fat cells in the blood appears to help obese rhesus monkeys lose weight, a new study suggests. Thu, 10 Nov 2011 08:15:20 -0500 http://www.foxnews.com/health/2011/11/10/drug-kills-fat-cells-in-obese-monkeys/ Obese monkeys saw their waistlines shrink in just weeks after scientists gave them an experimental drug that zaps fat cells, a study out today said, giving hope that such a pill for humans could be on the horizon. Thu, 10 Nov 2011 08:05:20 -0500 http://www.latimes.com/health/la-he-drug-fat-loss-20111110,0,5914182.story A synthetic peptide that inhibits blood supply, a strategy employed in many cancer drugs, is found to kill fat cells and improve metabolic function in trials involving monkeys. Thu, 10 Nov 2011 07:55:20 -0500 http://www.cbsnews.com/8301-504763_162-57322388-10391704/porky-primates-may-help-hefty-humans-slim-down/ (CBS) What do skinny monkeys have to say about fighting flab in humans? Quite a lot, as it turns out. Thu, 10 Nov 2011 07:50:35 -0500 http://www.foxbusiness.com/industries/2011/11/10/arrowhead-obesity-drug-shows-promise-in-study/ Arrowhead Research (ARWR: 0.70, -0.05, -6.08%), which makes medicines in oncology and obesity based on nanotechnology, says its weight-loss drug has been performing well in a study involving obese monkeys. Thu, 10 Nov 2011 07:43:15 -0500 http://healthland.time.com/2011/11/10/drug-based-on-cancer-treatment-shows-promise-for-weight-loss/ An experimental drug developed from cancer research showed early promise in a study of weight loss, researchers report, causing fat monkeys to shed an average 11% of their body weight after just a month of treatment. Thu, 10 Nov 2011 07:32:15 -0500 http://www.arrowres.com/publications/2011/november10_2011.html PASADENA, Calif. - November 10, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the publication of data from Ablaris Therapeutics, Inc.'s lead drug candidate, AdipotideTM, demonstrating weight loss and reduction in body mass index and abdominal circumference in obese rhesus monkeys. Thu, 10 Nov 2011 07:05:20 -0500 http://online.wsj.com/article/SB10001424052970203537304577028142340709990.html Treatment Targeting Fat Cells Caused Significant Weight Loss in Monkeys; Human Trials to Begin Soon Thu, 10 Nov 2011 02:38:13 -0500 http://www.msnbc.msn.com/id/45224080/ns/health-diet_and_nutrition/ A simple medication that leads to weight loss with no dieting or exercise could be a big step toward every dieter's dream. The study is only in monkeys, but tests in people could begin shortly. Wed, 9 Nov 2011 02:38:13 -0500 http://www.businessweek.com/news/2011-11-09/obese-monkeys-lose-weight-as-drug-targets-blood-vessels-in-fat.html Nov. 9 (Bloomberg) -- Obese rhesus monkeys lost an average of 11 percent of their body weight on an experimental drug that cut off the blood supply to fat tissue, raising the possibility the treatment may work in humans, researchers said. Wed, 9 Nov 2011 02:38:13 -0500 http://health.usnews.com/health-news/diet-fitness/diet/articles/2011/11/09/experimental-drug-slims-obese-monkeys WEDNESDAY, Nov. 9 (HealthDay News) - An experimental drug that targets and kills fat cells in the blood appears to help obese rhesus monkeys lose weight, a new study suggests. Wed, 9 Nov 2011 02:38:13 -0500 http://news.sciencemag.org/sciencenow/2011/11/new-obesity-therapy-monkeys.html?ref=hp More than 10 years ago, a husband-and-wife team came up with a novel way to fight disease: Look for small bits of protein that home in on specific tissues and attach a drug to them. Now, the work has brought the researchers close to a new therapy for obesity, which they report works well in monkeys and is edging toward human testing. Wed, 9 Nov 2011 02:38:13 -0500 http://abcnews.go.com/Health/drug-attacks-fat-helps-obese-monkeys-slim/story?id=14915646 Scientists have developed a new drug that attacks excess body fat, and a new study reports that it helped a small group of obese monkeys lose weight. Experts say the drug's fat-attack mechanism is an intriguing approach to weight loss, but questions remain about the drug's effectiveness and safety in humans. Wed, 9 Nov 2011 02:38:13 -0500 http://www.arrowres.com/publications/2011/november7_2011.html PASADENA, Calif. - November 7, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the publication of a white paper providing an overview of its proprietary dynamic polyconjugate (DPC) technology for safe and effective delivery of siRNA. Mon, 07 Nov 2011 04:09:21 -0400 http://www.arrowres.com/publications/2011/november3_2011.html PASADENA, Calif. - November 3, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that it has appointed Brendan P. Rae, Ph.D., J.D., to the position of Chief Business Officer, effective November 1, 2011. Thu, 03 Nov 2011 04:09:21 -0400 http://www.arrowres.com/publications/2011/november2_2011.html PASADENA, Calif. - November 2, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that a paper further validating the drug development programs of Ablaris Therapeutics, Inc., a subsidiary of Arrowhead, and Alvos Therapeutics, Inc., was published in the Proceedings of the National Academy of Sciences ("PNAS"), one of the world's most cited multidisciplinary journals covering the biological, physical, and social sciences. Wed, 02 Nov 2011 17:09:21 -0400 http://www.arrowres.com/publications/2011/october27_2011.html PASADENA, Calif. - October 27, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has appointed Bruce Given, M.D. to the position of Chief Operating Officer of the Company effective October 26, 2011. Thu, 27 Oct 2011 05:05:00 -0400 http://www.mdanderson.org/newsroom/news-releases/2011/blood-vessel-mapping-reveals-four-new-zip-codes-.html A research team led by scientists from The University of Texas MD Anderson Cancer Center have discovered four new "ZIP codes" in their quest to map the vast blood vessel network of the human body. Mon, 24 Oct 2011 07:00:00 -0400 http://www.arrowres.com/publications/2011/october24_2011.html PASADENA, Calif. - October 24, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), today announced that it has acquired RNA therapeutics assets from Roche (SIX: RO, ROG; OTCQX: RHHBY) including the state-of-the-art research site in Madison, WI. Mon, 24 Oct 2011 01:00:00 -0400 http://www.arrowres.com/publications/2011/october4_2011.html PASADENA, Calif. - October 4, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that on September 30, 2011, it closed a private placement of approximately 14.5 million shares of common stock priced at market for $0.38 per share. Tue, 04 Oct 2011 01:00:00 -0400 http://www.arrowres.com/publications/2011/august08_2011.html PASADENA, Calif. - August 8, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal 2011 third quarter ended June 30, 2011. Mon, 08 Aug 2011 01:00:00 -0400 http://www.arrowres.com/publications/2011/august01_2011.html PASADENA, Calif. - August 1, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will report its financial results for the fiscal 2011 third quarter ended June 30, 2011, on Monday, August 8, 2011 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the conference call, please dial 1-800-860-2442 (toll free from the U.S. and Canada), or 412-858-4600 (for international callers). Investors may also access a live audio webcast of this conference call on the Company's website at www.arrowheadresearch.com. Mon, 01 Aug 2011 11:30:00 -0400 http://www.arrowres.com/publications/2011/july26_2011.html PASADENA, Calif. - July 26, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that Timothy J. Triche, M.D., Ph.D., Professor of Pathology and Pediatrics at the University of Southern California ('USC') Keck School of Medicine, has agreed to join the Scientific Advisory Board ("SAB") of Arrowhead's majority owned subsidiary Calando Pharmaceuticals, Inc. Tue, 26 Jul 2011 11:30:00 -0400 http://www.arrowres.com/publications/2011/june21_2011.html PASADENA, Calif. - June 21, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and Chief Executive Officer Christopher Anzalone, Ph.D., will present at two upcoming nanomedicine-focused events at the Copthorne Tara Hotel in London. Tue, 21 Jun 2011 11:47:00 -0400 http://www.uthouston.edu/media/story.htm?id=3207721 HOUSTON, TX - June 16, 2011 - Innovative adult stem cell research by scientists at The University of Texas Health Science Center at Houston (UTHealth) could aid efforts to apply the brakes to stem cells that produce the type of fat ringing the waists of millions. Research appeared today online ahead of the print issue of Cell Stem Cell. Thu, 16 Jun 2011 11:40:00 -0400 http://www.arrowres.com/publications/2011/june16_2011.html PASADENA, Calif. - June 16, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and CEO Christopher Anzalone, Ph.D., was featured in a Medical Research, Diagnostic Substances & Life Science Tools Report published by The Wall Street Transcript. Thu, 16 Jun 2011 11:35:00 -0400 http://www.arrowres.com/publications/2011/june09_2011.html PASADENA, Calif. - June 9, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that, on June 7, 2011, it received a notification from the NASDAQ Stock Market indicating that the Company will have an additional 180-day grace period, until December 5, 2011 to regain compliance with NASDAQ's $1.00 minimum bid requirement. Thu, 09 Jun 2011 11:45:00 -0400 http://www.methodisthealth.com/tmhri.cfm?id=40688 HOUSTON (May 17, 2011) - Mauro Ferrari, Ph.D. , president and CEO of The Methodist Hospital Research Institute in Houston, recently received the 2011 CRS Founders' Award. The prestigious, internationally-recognized Founders Award honors outstanding leaders in the field of bioactive material delivery science. Tue, 17 May 2011 11:25:00 -0400 http://www.arrowres.com/publications/2011/may12_2011.html PASADENA, Calif. - May 12, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal 2011 second quarter ended March 31, 2011. Thu, 12 May 2011 11:35:00 -0400 http://www.arrowres.com/publications/2011/may04_2011.html PASADENA, Calif. - May 4, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that it will report its financial results for the fiscal 2011 second quarter ended March 31, 2011, on Thursday, May 12, 2011 at 4:30 p.m. Eastern time(1:30 p.m. Pacific time). Wed, 04 May 2011 11:35:00 -0400 http://www.arrowres.com/publications/2011/may03_2011.html PASADENA, Calif. - May 3, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that Dr. Christopher Anzalone, Chief Executive Officer, will present at the 2011 MDB Capital Group Bright Lights Conference at 2:00 p.m. ET on Tuesday, May 10, 2011. The conference will feature over 40 of the most innovative companies with disruptive and market changing IP. The event is being held at the Le Parker Meridien Hotel in New York City. Tue, 03 May 2011 11:35:00 -0400 http://www.arrowres.com/publications/2011/april27_2011.html PASADENA, Calif. - April 27, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that John J. Rossi, Ph.D., a pioneer and one of the world leaders in the field of RNAi discovery and development, has joined majority owned subsidiary Calando Pharmaceuticals, Inc. as a senior advisor. Dr. Rossi, who is also one of the co-founders of Calando, will be the first member of Calando's new Scientific Advisory Board. Wed, 27 Apr 2011 11:30:00 -0400 http://www.arrowres.com/publications/2011/april06_2011.html PASADENA, Calif. - April 6, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that majority-owned subsidiary Ablaris Therapeutics, Inc. has completed a second closing of its Series A financing round for gross proceeds of $1.2 million, with aggregate gross proceeds of $2.9 million to date. Wed, 06 Apr 2011 11:30:00 -0400 http://www.arrowres.com/publications/2011/march08_2011.html PASADENA, Calif. - March 8, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that Dr. Christopher Anzalone, Chief Executive Officer, will present at the Roth 23rd Annual OC Growth Stock Conference at 11:30 a.m. Tue, 08 Mar 2011 11:30:00 -0400 http://www.arrowres.com/publications/2011/february10_2011.html PASADENA, Calif. - February 10, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal 2011 first quarter ended December 31, 2010. Thu, 10 Feb 2011 11:30:00 -0400 http://www.arrowres.com/publications/2011/february9_2011.html PASADENA, Calif. - February 9, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company, today announced that Dr. Christopher Anzalone, Chief Executive Officer, will present at the 13th Annual BIO CEO and Investor Conference at 8:00 a.m. Eastern time on Monday, February 14, 2011 at the Waldorf-Astoria Hotel in New York City, New York. Dr. Anzalone will be discussing recent Company developments and its opportunities in nanomedicine. Wed, 09 Feb 2011 11:30:00 -0400 http://www.arrowres.com/publications/2011/february06_2011.html PASADENA, Calif. - February 4, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a focused nanomedicine holding company, today announced that it will report its financial results for the fiscal 2011 first quarter ended December 31, 2010, on Thursday, February 10, 2011 after the market closes. Arrowhead management will host a conference call the same day to discuss those results and recent events at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). Sun, 06 Feb 2011 11:30:00 -0400 http://www.fastcompany.com/magazine/152/molecular-healing.html As seen in Fast Company, February 2011 issue. The article features Dr. Sam Stupp, founder of Nanotope, Inc., an Arrowhead portfolio company commercializing regenerative medicine technology developed by Dr. Stupp and his colleagues at Northwestern University. The article describes Dr. Stupp's interdisciplinary approach to technology development, marrying materials science and biology to promote healing of neural and other tissues. Tue, 01 Feb 2011 12:00:00 -0400 http://www.arrowheadresearch.com/publications/2011/january18_2011-2.html PASADENA, Calif. - January 18, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR) ("the Company") today announced that it has invested $1 million in its majority owned subsidiary, Calando Pharmaceuticals, and converted approximately $8M of Calando debt to Arrowhead into equity. Tue, 18 Jan 2011 11:45:00 -0400 http://www.arrowheadresearch.com/publications/2011/january18_2011.html PASADENA, Calif. - January 18, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its Unidym, Inc. subsidiary has been acquired by Wisepower Co., Ltd., a publicly-traded, Seoul, Korea-based electronics company (KOSDAQ: 040670). Tue, 18 Jan 2011 11:35:00 -0400